The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.
 
Yara L. Verschoor
No Relationships to Disclose
 
José van den Berg
No Relationships to Disclose
 
Geerard Beets
No Relationships to Disclose
 
Karolina Sikorska
No Relationships to Disclose
 
Arend Aalbers
No Relationships to Disclose
 
Anja van Lent
No Relationships to Disclose
 
Cecile Grootscholten
No Relationships to Disclose
 
Inge Huibregtse
No Relationships to Disclose
 
Hendrik Marsman
No Relationships to Disclose
 
Steven Oosterling
No Relationships to Disclose
 
Marieke van de Belt
No Relationships to Disclose
 
Marleen Kok
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo (Inst); Bristol-Myers Squibb/Medarex (Inst); MSD (Inst); Roche (Inst)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
 
Ton Schumacher
Consulting or Advisory Role - Allogene Therapeutics; Asher Biotherapeutics; Merus NV; Neogene Therapeutics; Scenic Biotech
Patents, Royalties, Other Intellectual Property - IP related to the CD47 immune checkpoint, licensed by Scenic Biotech
 
Monique E van Leerdam
No Relationships to Disclose
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); POEM Health (Inst); Roche/Genentech (Inst); Sanofi (Inst); T-Knife (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Emile E. Voest
Consulting or Advisory Role - Aglaia BioMedical Ventures (Inst); Biogeneration Ventures; InteRNA; Life Sciences Partners (Inst); Roche Pharma AG (Inst); Servier (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)
 
Myriam Chalabi
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)